Radium-223 imaging study for men with prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This study uses a special type of scan (quantitative SPECT) to measure how Radium-223 (Xofigo) works in your bones. It helps doctors better understand treatment for prostate cancer that has spread to the bones.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have prostate cancer that has spread to at least 3 spots in your bones and is no longer responding to hormone therapy.
- You are able to receive Radium-223 (Xofigo) treatment.
- You are 18 years or older.
- You are able to lie still on your back for 45–60 minutes for a scan.
- You do not have cancer that has spread mostly to organs like the liver or lungs.
- You do not have other serious medical conditions like uncontrolled infections or heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses special scans (SPECT imaging) to see how radium or lutetium treatments move through your body, helping doctors plan better doses. It's for people with advanced prostate cancer (getting Radium-223) or advanced neuroendocrine tumors (getting 177Lu treatments).
This Phase 2 trial tests a radiation-focused approach for people with newly diagnosed (de novo) prostate cancer that has spread to a small number of spots, especially in bone. It aims to see how well the treatment controls the cancer while keeping side effects manageable.
This trial studies a new imaging agent called RAX301, which may help doctors see prostate cancer more clearly during a PET/CT scan. It is being tested in two groups of men: those scheduled for prostate removal surgery and those with a rising PSA after previous treatment.
This research study tests a new imaging scan (called 68Ga-OncoACP3-PET/CT) to help find prostate cancer and see where it may have spread. The scan uses a radioactive tracer to help doctors visualize cancer cells and decide on the best treatment options.
This trial uses a special imaging scan (SPECT/CT) with a small amount of radioactive tracer to look at prostate cancer. It aims to see how well the scan matches your prostate cancer tests and may help improve detection and assessment.
This trial uses a special PET scan (POSLUMA) before and after radiation to see if it helps treat prostate cancer that has spread to a few spots outside the pelvis. It's for men whose cancer still responds to hormone therapy and who have not had widespread spread.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.